Sorrento gains FDA approval for ZTlido

USA-based Sorrento Therapeutics (Nasdaq: SRNE) and its majority-owned subsidiary, Scilex Pharmaceuticals, received approval from the US Food and Drug Administration for ZTlido (lidocaine topical system) 1.8%.

ZTlido is indicated for the relief of pain associated with post-herpetic neuralgia (PHN), also referred to as post-shingles pain. ZTlido is a major advancement in analgesics because of its proprietary adhesion technology demonstrating 12-hour wear with efficient lidocaine delivery, even during exercise.

According to recent IMS data, more than 100 million prescription lidocaine patches were sold in the US in 2017. Sorrento intends to have Scilex complete the final steps necessary to commercial launch of ZTlido in the USA with the objective to make the product commercially available to patients sometime in 2018.